Halozyme Therapeutics Stock Buy Hold or Sell Recommendation
| HALO Stock | USD 65.16 0.84 1.31% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Halozyme Therapeutics is 'Buy'. The recommendation algorithm takes into account all of Halozyme Therapeutics' available fundamental, technical, and predictive indicators you will find on this site.
Check out Halozyme Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide. In addition, we conduct extensive research on individual companies such as Halozyme and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Halozyme Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Halozyme |
Execute Halozyme Therapeutics Buy or Sell Advice
The Halozyme recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Halozyme Therapeutics. Macroaxis does not own or have any residual interests in Halozyme Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Halozyme Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Buy
Market Performance | Strong | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Halozyme Therapeutics Trading Alerts and Improvement Suggestions
| Halozyme Therapeutics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from kalkinemedia.com: How Is Halozyme Therapeutics Navigating Market Trends |
Halozyme Therapeutics Returns Distribution Density
The distribution of Halozyme Therapeutics' historical returns is an attempt to chart the uncertainty of Halozyme Therapeutics' future price movements. The chart of the probability distribution of Halozyme Therapeutics daily returns describes the distribution of returns around its average expected value. We use Halozyme Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Halozyme Therapeutics returns is essential to provide solid investment advice for Halozyme Therapeutics.
| Mean Return | 0.47 |
| Value At Risk | -1.45 |
| Potential Upside | 2.54 |
| Standard Deviation | 1.45 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Halozyme Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Halozyme Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Halozyme Therapeutics, soars without any apparent reason. This usually happens because many institutional investors are aggressively trading Halozyme Therapeutics back and forth among themselves. Companies that invest excess capital in these types of assets may also be included in this term and can influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 1.9 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 1.9 M | |
| Northern Trust Corp | 2024-12-31 | 1.8 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.8 M | |
| Gw&k Investment Management, Llc | 2024-12-31 | 1.7 M | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.6 M | |
| Nuveen Asset Management, Llc | 2024-12-31 | 1.5 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-12-31 | 1.5 M | |
| Artisan Partners Limited Partnership | 2024-12-31 | 1.4 M | |
| Blackrock Inc | 2024-12-31 | 17.6 M | |
| Vanguard Group Inc | 2024-12-31 | 13.3 M |
Halozyme Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 27.5M | (29.0M) | 115.5M | (116.3M) | (2.5M) | (2.4M) | |
| Free Cash Flow | 53.0M | 298.0M | 235.3M | 373.3M | 468.4M | 491.8M | |
| Other Non Cash Items | 13.6M | 24.6M | 9.9M | (10.3M) | (979K) | (930.1K) | |
| Capital Expenditures | 2.5M | 1.5M | 4.8M | 15.3M | 10.7M | 11.2M | |
| Net Income | 129.1M | 402.7M | 202.1M | 281.6M | 444.1M | 466.3M | |
| End Period Cash Flow | 148.2M | 119.2M | 234.7M | 118.4M | 115.9M | 83.8M | |
| Change To Inventory | (31.4M) | 7.4M | (17.5M) | (26.9M) | (67.4M) | (64.0M) | |
| Depreciation | 3.3M | 3.0M | 49.6M | 84.9M | 81.3M | 85.4M | |
| Change Receivables | (29.4M) | (38.3M) | 6.8M | (83.9M) | (75.5M) | (71.8M) | |
| Change To Netincome | 36.1M | 16.4M | (113.6M) | 67.0M | 60.3M | 63.3M | |
| Net Borrowings | 339.0M | (19.6M) | 415.8M | 617.4M | 710.1M | 745.6M | |
| Investments | 79.8M | (404.8M) | 490.9M | (96.9M) | (262.7M) | (249.6M) |
Halozyme Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Halozyme Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Halozyme Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Halozyme stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.50 | |
β | Beta against Dow Jones | 0.50 | |
σ | Overall volatility | 1.39 | |
Ir | Information ratio | 0.37 |
Halozyme Therapeutics Volatility Alert
Halozyme Therapeutics has relatively low volatility with skewness of 0.88 and kurtosis of 3.52. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Halozyme Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Halozyme Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Halozyme Therapeutics Fundamentals Vs Peers
Comparing Halozyme Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Halozyme Therapeutics' direct or indirect competition across all of the common fundamentals between Halozyme Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Halozyme Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Halozyme Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Halozyme Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Halozyme Therapeutics to competition |
| Fundamentals | Halozyme Therapeutics | Peer Average |
| Return On Equity | 1.98 | -0.31 |
| Return On Asset | 0.18 | -0.14 |
| Profit Margin | 0.44 % | (1.27) % |
| Operating Margin | 0.59 % | (5.51) % |
| Current Valuation | 8.96 B | 16.62 B |
| Shares Outstanding | 123.53 M | 571.82 M |
| Shares Owned By Insiders | 1.15 % | 10.09 % |
| Shares Owned By Institutions | 98.85 % | 39.21 % |
| Number Of Shares Shorted | 9.22 M | 4.71 M |
| Price To Earning | 60.08 X | 28.72 X |
| Price To Book | 22.13 X | 9.51 X |
| Price To Sales | 7.93 X | 11.42 X |
| Revenue | 1.02 B | 9.43 B |
| Gross Profit | 776.86 M | 27.38 B |
| EBITDA | 656.54 M | 3.9 B |
| Net Income | 444.09 M | 570.98 M |
| Cash And Equivalents | 209.36 M | 2.7 B |
| Cash Per Share | 1.52 X | 5.01 X |
| Total Debt | 1.51 B | 5.32 B |
| Debt To Equity | 4.28 % | 48.70 % |
| Current Ratio | 2.72 X | 2.16 X |
| Book Value Per Share | 2.96 X | 1.93 K |
| Cash Flow From Operations | 479.06 M | 971.22 M |
| Short Ratio | 8.35 X | 4.00 X |
| Earnings Per Share | 3.43 X | 3.12 X |
| Price To Earnings To Growth | (2.50) X | 4.89 X |
| Target Price | 66.11 | |
| Number Of Employees | 350 | 18.84 K |
| Beta | 1.32 | -0.15 |
| Market Capitalization | 8.05 B | 19.03 B |
| Total Asset | 2.06 B | 29.47 B |
| Retained Earnings | 359.87 M | 9.33 B |
| Working Capital | 946.24 M | 1.48 B |
Note: Disposition of 17409 shares by Nicole LaBrosse of Halozyme Therapeutics subject to Rule 16b-3 [view details]
Halozyme Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Halozyme . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Halozyme Therapeutics Buy or Sell Advice
When is the right time to buy or sell Halozyme Therapeutics? Buying financial instruments such as Halozyme Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Halozyme Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Millennials Best Thematic Idea Now
Millennials Best
Companies or funds that provide products or services that appeal to the generation of millennials and that are expected to experience growth in the next 5 years. The millennial generation usually refers to the demographic population that were born between 1980 to 2000. The Millennials Best theme has 49 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Millennials Best Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Halozyme Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Halozyme Stock, please use our How to Invest in Halozyme Therapeutics guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Halozyme Therapeutics. If investors know Halozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Halozyme Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.623 | Earnings Share 3.43 | Revenue Per Share | Quarterly Revenue Growth 0.295 | Return On Assets |
The market value of Halozyme Therapeutics is measured differently than its book value, which is the value of Halozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Halozyme Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Halozyme Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Halozyme Therapeutics' market value can be influenced by many factors that don't directly affect Halozyme Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Halozyme Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Halozyme Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Halozyme Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.